Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers: Still An Opportunity Yielding Over 4%
Bristol-Myers Squibb has rallied over 35% in the past 6 months, with shares approaching $60 and a price target of $70. BMY's strong dividend yield exceeds 4%, and strategic acquisitions are expected to boost future EPS and financial stability. Despite risks like patent expirations and competition, BMY's robust pipeline and R&D investments position it well for future growth.
BMY vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
Bristol Myers (BMY) Upgraded to Buy: Here's Why
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol Myers A Top Socially Responsible Dividend Stock With 4% Yield
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.
Bristol-Myers Squibb Company (BMY) Citi's 2024 Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Bristol-Myers Squibb (BMY -0.08%) is the kind of stock that potentially has a lot to offer to investors looking for wealth-building investments. With a large repertoire of medicines on the market, and a constant stream of programs approaching maturity and a shot at getting approved for sale, there's no question that the business will continue to create drugs that are in demand around the world.
3 Magnificent S&P 500 Dividend Stocks Down 27%, 28%, and 29% to Buy and Hold Forever
Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold forever is a different story.
BMY Stock vs. JNJ Stock
Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its forward expected earnings (2025), versus 14.7x for JNJ.
